Crescent Biopharma, Inc. Common Stock (CBIO) is a publicly traded Healthcare sector company. As of May 21, 2026, CBIO trades at $18.94 with a market cap of $511.51M and a P/E ratio of -243.63. CBIO moved +3.63% today. Year to date, CBIO is +70.21%; over the trailing twelve months it is flat. Its 52-week range spans $8.72 to $27.41. Analyst consensus is strong buy with an average price target of $29.50. Rallies surfaces CBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Crescent Biopharma, Inc. Common Stock (CBIO) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. CBIO moved +3.63% today. Analyst consensus is strong buy.
| Metric | Value |
|---|---|
| Price | $18.94 |
| Market Cap | $511.51M |
| P/E Ratio | -243.63 |
| EPS | $-0.08 |
| Dividend Yield | 0.00% |
| 52-Week High | $27.41 |
| 52-Week Low | $8.72 |
| Volume | 100.27K |
| Avg Volume | 0 |
| Revenue (TTM) | $117.05M |
| Net Income | $-1.39M |
| Gross Margin | 95.09% |
7 analysts cover CBIO: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $29.50.